Amgen receives CHMP positive opinion for IMLYGIC (TM) (talimogene laherparepvec)

IMLYGIC is first oncolytic immunotherapy to demonstrate therapeutic benefit for patients with advanced melanoma

Source: Pharmacy Europe - October 26, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Oncology Research advanced melanoma chmp IMLYGIC immunotherapy Latest News oncolytic immunotherapy talimogene laherparepvec Source Type: news